ARN-75039 for Lassa Fever

This trial tests a new antiviral pill, ARN-75039, for treating Lassa fever, a serious viral illness, in hospitalized patients. The researchers aim to assess the safety and effectiveness of this new treatment compared to the usual intravenous drug, ribavirin. Participants will be divided into three groups to receive either a high dose or low dose of ARN-75039 or ribavirin, with the study tracking their recovery and any side effects. The trial seeks adults who have tested positive for Lassa fever and require hospital care. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant medical advancements.

The trial requires that you have not received specific drug therapy for Lassa fever, like ribavirin or other antivirals, within 15 days before joining. It doesn't specify about other medications, so it's best to discuss your current medications with the trial team.

Earlier studies have shown that ARN-75039 is safe and well-tolerated in people. Research suggests that this antiviral drug effectively protects against the Lassa virus in animal tests, including those with guinea pigs. Additionally, previous studies with healthy participants found that ARN-75039 was well-tolerated at various doses, with no serious side effects reported. This evidence supports the safety of ARN-75039 as it undergoes testing in current clinical trials for treating Lassa fever.¹²³⁴⁵

Unlike the standard of care for Lassa Fever, which typically involves intravenous Ribavirin, ARN-75039 is an oral antiviral agent. Researchers are excited because ARN-75039 offers a potentially more convenient oral administration, which could be easier for patients to manage compared to intravenous treatments. Additionally, ARN-75039 targets the virus in a new way, which might lead to improved outcomes or reduced side effects. The high and low dose regimens allow for flexibility in treatment based on patient needs, which could further enhance its effectiveness and safety profile.

Research has shown that ARN-75039, a new oral antiviral drug, could effectively treat Lassa fever. In animal studies, those given ARN-75039 exhibited few signs of illness and had no detectable virus in their blood, suggesting the drug may help reduce the virus in the body. ARN-75039 targets a part of the virus crucial for entering cells and causing infection. Early studies have demonstrated that the drug is both effective against the virus and safe to use. These results support further testing of ARN-75039 as a potential treatment for Lassa fever. Participants in this trial will receive either a high or low oral dose of ARN-75039 or the standard of care, Ribavirin intravenous (IV).¹²⁶⁷⁸